<- Go Home
NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Market Cap
$2.1B
Volume
536.5K
Cash and Equivalents
$748.4M
EBITDA
-$189.6M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$47.1M
Profit Margin
100.00%
52 Week High
$27.29
52 Week Low
$14.06
Dividend
N/A
Price / Book Value
N/A
Price / Earnings
-10.23
Price / Tangible Book Value
N/A
Enterprise Value
$1.3B
Enterprise Value / EBITDA
-6.70
Operating Income
-$189.7M
Return on Equity
31.51%
Return on Assets
-18.15
Cash and Short Term Investments
$808.5M
Debt
$389.0K
Equity
$777.4M
Revenue
$47.1M
Unlevered FCF
-$99.0M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium